Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma
Authors:
- 1 July 2015
- journal article
- case report
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 151 (7) , 797-9
Abstract
Case Report from JAMA Dermatology — Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal MelanomaKeywords
This publication has 6 references indexed in Scilit:
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialThe Lancet, 2014
- PD-1 Pathway Inhibitors: Changing the Landscape of Cancer ImmunotherapyCancer Control, 2014
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma CancerJournal of Immunotherapy, 2012
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV MelanomaClinical Cancer Research, 2011
- Paradoxical Reactions to Targeted Biological Treatments: A Way to Treat and Trigger?Acta Dermato-Venereologica, 2010